These results demonstrate that anti-PTK7 mAbs significantly reduce both tumor volume and weight in the TNBC xenograft mouse model, with relative efficacy ranked as 43-m, 52-m, 32-m, and 50-m. This evidence concerns the gene PTK7 and neoplasm.